Studies have shown that the one-dose coronavirus vaccine by Johnson and Johnson is 66% effective at preventing moderate to severe illness and 85% effective against the more serious symptoms.
However, studies showed that this vaccine may be less effective against the variant spreading in South Africa, where the efficiency rate stood at only 57% in the trials conducted by J&J.
After undertaking a global study involving 44,000 participants, the United States pharmaceutical cooperation said that the results showed “there were no cases of hospitalisation or death among those volunteers who had received the vaccine’”.
Although the efficiency rate at 66% provides significantly less protection than Pfizer, Moderna and the Oxford vaccine, the single-dose approach is likely to speed up the vaccination process and will appeal especially to those countries with very high cases.
Dr. Paul Stoffels, the chief scientific officer at J&J said: “A one-shot vaccine is considered by the World Health Organization to be the best option in pandemic settings.”
The vaccine is cheap compared to others and also does not require extremely cold temperatures for transportation and storage. The United Kingdom has already pre-ordered 30 million doses of the vaccine and the US 100 million.